热门资讯> 正文
Thomna PBM Express宣布将Humira从许多处方药库中删除
2024-08-27 03:03
- AbbVie's Humira (adalimumab) will be taken off the formulary lists of many Cigna (NYSE:CI) health care plans in 2025 in favor of cheaper biosimilar version.
- Members next year can get Simlandi from Teva (TEVA) and Alvotech (ALVO), Cyltezo from Boehringer Ingelheim, or an unbranded version of Hyrimoz from Novartis (NVS) division Sandoz.
- Despite the introduction of many Humira biosimilars, AbbVie still controls most of the market for adalimumab thanks to deals made with pharmacy benefit managers, according to Reuters.
- In January, CVS Health said that its Caremark PBM would remove Humira from its commercial formularies on April 1.
More on Cigna
- Cigna Group: Services Focus Leads To Outperformance
- Cigna: Game Over For PBMs?
- The 'battleground' stocks shorted by hedge funds but owned by many long-only portfolios
- The Cigna Group (CI) Q2 2024 Earnings Call Transcrip
- The U.S. uninsured rate hits 8%, a post-pandemic high
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
